Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CCR6 | P51684 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2446348 | 1.00 | ALDH1A1 (0.48) | ALDH1A1DPP4POLBSMN1; SMN2MAPT | |
| SCHEMBL2446346 | 0.91 | ALDH1A1 (0.42) | ALDH1A1DPP4POLBSMN1; SMN2LMNA | |
| SCHEMBL14521230 | 0.89 | ALDH1A1 (0.41) | ALDH1A1DPP4POLBSMN1; SMN2 | |
| SCHEMBL612188 | 0.89 | ALDH1A1 (0.41) | ALDH1A1DPP4POLBSMN1; SMN2 | |
| SCHEMBL4342168 | 0.86 | ALDH1A1 (0.38) | ALDH1A1DPP4POLBSMN1; SMN2 | |
| SCHEMBL16191438 | 0.84 | ALDH1A1 (0.37) | ALDH1A1DPP4POLBSMN1; SMN2 | |
| Acrylamide SCHEMBL7521468 | 0.84 | ALDH1A1 (0.39) | ALDH1A1DPP4POLB | |
| SCHEMBL12610741 | 0.82 | ALDH1A1 (0.38) | ALDH1A1DPP4POLBSMN1; SMN2 | |
| SCHEMBL2187457 | 0.81 | ALDH1A1 (0.45) | ALDH1A1DPP4POLBSMN1; SMN2MAPT | |
| SCHEMBL19717802 | 0.80 | PDE4A (0.47) | ALDH1A1DPP4POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818778-B2 | HYDROLYSIS OF OCTAETHYL(-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXAMIDE OBTAINED BY CONDENSATION OF N,N,N',N'-TETRAALKYL-D-TARTARAMIDE WITH DIHALO- OR DISULFONYLOXY- DIETHYL ETHER | RSTECH CO., LTD. (KR) | 2004-11-16 | — | — | US | claimed |
| US-20040044231-A1 | Process for preparing (-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | RSTECH CO., LTD. (KR) | 2004-03-04 | — | — | US | claimed |
| WO-2002042288-A1 | PROCESS FOR PREPARING (-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXYLIC ACID, AND (-)-CHIRAL STATIONARY PHASES FOR RESOLUTION OF RACEMIC COMPOUNDS USING THE SAME | RSTECH CO., LTD (KR) | 2002-05-30 | — | — | WO | claimed |
| US-20070087936-A1 | Recording medium and method of manufacturing inkjet recording medium | FUJIFILM CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087936-A1 | Recording medium and method of manufacturing inkjet recording medium | FUJIFILM CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-6818778-B2 | HYDROLYSIS OF OCTAETHYL(-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXAMIDE OBTAINED BY CONDENSATION OF N,N,N',N'-TETRAALKYL-D-TARTARAMIDE WITH DIHALO- OR DISULFONYLOXY- DIETHYL ETHER | RSTECH CO., LTD. (KR) | 2004-11-16 | — | — | US | disclosed |
| US-20040044231-A1 | Process for preparing (-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | RSTECH CO., LTD. (KR) | 2004-03-04 | — | — | US | disclosed |
| WO-2002042288-A1 | PROCESS FOR PREPARING (-)-(18-CROWN-6)-2,3,11,12-TETRACARBOXYLIC ACID, AND (-)-CHIRAL STATIONARY PHASES FOR RESOLUTION OF RACEMIC COMPOUNDS USING THE SAME | RSTECH CO., LTD (KR) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044231-A1 | Process for preparing (-)-(18-crown-6)-2,3,11,12-tetracarboxylic acid, and (-)-chiral stationary phases for resolution of racemic compounds using the same | CCR6, CCR1, CCR9 | ALDH1A1 519/4885DPP4 1501/4885POLB 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.